Incidence and risk of rash to mTOR inhibitors in cancer patients – a meta-analysis of randomized controlled trials

References

• Dabney R, Devine R, Sein N, George B. New agents in renal cell carcinoma. Target Oncol Epub 2013 Nov 16.
   Google Scholar
• Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: Development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009;2:45.
   PubMed Web of Science ®Google Scholar
• Khokhar NZ, Altman JK, Platanias LC. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Curr Opinion Oncol 2011;23:578–86.
   PubMed Web of Science ®Google Scholar
• Martins F, de Oliveira MA, Wang Q, Sonis S, Gallottini M, George S, et al. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol 2013;49:293–8.
   PubMed Web of Science ®Google Scholar
• Carpenter JT, Roche H, Campone M, Colomer R, Jagiello-Gruszfeld A, Moore L, et al. Randomized 3-arm, phase 2 study of temsirolimus (CCL-779) in combination with letrozole in post-menopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2007; 23:16s: abstract 564.
   Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. New Engl J Med 2011;364: 514–23.
   PubMed Web of Science ®Google Scholar
• Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis placebo-controlled trial. Lancet 2013;1:817–24.
   Web of Science ®Google Scholar
• Ohtsu A, Ajani JA, Bai YX, Bany YJ, Chung HC, Pan HM, et al. Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 2013;31:3935–43.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 2010;116:4256–65.
   PubMed Web of Science ®Google Scholar
• Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex phase 3 trial. Lancet 2013;1:125–32.
   Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. New Engl J Med 2012;366:520–9.
   PubMed Web of Science ®Google Scholar
• Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol 2012;30:2718–24.
   PubMed Web of Science ®Google Scholar
• Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630–7.
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsh D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005–12.
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl J Med 2007; 356:2271–81.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013;31:195–202.
   PubMed Web of Science ®Google Scholar
• Balagula Y, Rosen ST, Lacouture ME. The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol 2011;65:624–35.
   PubMed Web of Science ®Google Scholar
• Ramirez-Fort MK, Case EC, Rosen AC, Cerci FB, Wu S, Lacouture ME, et al. Rash to the mTOR inhibitor everolimus systematic review and meta-analysis. Am J Clin Oncol Epub 2012 Dec 13.
   Google Scholar
• Gomez-Fernandez C, Garden BC, Wu S, Feldman DR, Lacouture ME. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis. Eur J Cancer 2012;48:340–6.
   PubMed Web of Science ®Google Scholar
• Hadoux J, Vignot S, De La Motte Rouge T. Renal cell carcinoma: Focus on safety and efficacy of temsirolimus. Clinical medicine insights. Oncology 2010;4:143–54.
   PubMedGoogle Scholar
• Balagula Y, Rosen A, Tan BH, Busam KJ, Pulitzer MP, Motzer RJ, et al. Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. Cancer 2012;118:5078–83.
   PubMed Web of Science ®Google Scholar
• Gandhi M, Kuzel T, Lacouture M. Eosinophilic rash secondary to temsirolimus. Clin Genitour Cancer 2009;7:E34–6.
   PubMed Web of Science ®Google Scholar
• Staehler M, Haseke N, Khoder W, Stief CG. Profile of temsirolimus in the treatment of advanced renal cell carcinoma. Onco Targets Ther 2010;3:191–6.
   PubMed Web of Science ®Google Scholar
• Paplomata E, Zelnak A, O’Regan R. Everolimus: Side effect profile and management of toxicities in breast cancer. Breast Cancer Res Treat 2013;140:453–62.
   PubMed Web of Science ®Google Scholar
• Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, et al. Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol 2012;67:1025–39.
   PubMed Web of Science ®Google Scholar